ArticleFrontiers in microbiology2026
Clove-mediated green synthesis of silver nanoparticles and
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Green synthesis of silver nanoparticles (AgNPs) using plant extracts offers an eco-friendly and sustainable strategy for developing multifunctional nanomaterials with biomedical applications. This study aimed to biosynthesize AgNPs using Methods: AgNPs were biosynthesized using clove extract and characterized by Ultraviolet-Visible Spectroscopy (UV-Vis), X-ray Diffraction (XRD), Transmission Electron Microscopy (TEM), and Energy-Dispersive X-ray Spectroscopy (EDX). Antioxidant activity was determined by IC₅₀ analysis, while anti-inflammatory potential was assessed using hemolysis protection and human red blood cell (HRBC) membrane stabilization assays. Antiviral activity was evaluated against hepatitis A virus (HAV), Coxsackievirus B4 (COXB4), and herpes simplex virus type 1 (HSV-1). Cytotoxicity was assessed in human colorectal carcinoma (CaCO₂) and normal lung fibroblast (Wi-38) cells. Antibacterial activity was tested against multidrug-resistant (MDR) bacterial strains, and quantitative molecular analyses were performed to determine the expression of bacterial virulence genes and cancer-related genes. All reported values represent the mean of three independent experiments. Results: The synthesized AgNPs were predominantly spherical, well dispersed, and had an average particle size of approximately 9.5 nm. XRD confirmed a crystalline face-centered cubic (fcc) structure, while UV-Vis analysis showed a characteristic surface plasmon resonance peak at 437 nm, confirming successful nanoparticle formation. The AgNPs exhibited strong antioxidant activity with an IC₅₀ of approximately 13.5 μg/mL and demonstrated significant anti-inflammatory activity through membrane stabilization and hemolysis protection. Antiviral assays showed marked inhibition of HAV, COXB4, and HSV-1 at 250 μg/mL, with the highest inhibition observed against HAV (74%). Cytotoxicity studies revealed selective anticancer activity, with an IC₅₀ of approximately 137 μg/mL against CaCO₂ cells compared with 387 μg/mL for Wi-38 cells. Broad-spectrum antibacterial activity was observed against MDR Discussion: Clove-mediated AgNPs demonstrated potent multifunctional biological activities, including antioxidant, anti-inflammatory, antiviral, selective anticancer, and antibacterial effects, accompanied by modulation of cancer-associated and bacterial virulence genes. These findings highlight the therapeutic potential of biosynthesized AgNPs as promising candidates for the development of novel antimicrobial and anticancer nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.